Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Proteosome and Lysosome Modulation as a Therapeutic Approach for CDKL5 Deficiency Disorder

FY 2025-26

Summary
Cyclin-dependant kinase-like 5 (CDKL5) deficiency disorder is a severe neurodevelopmental disorder caused by an X-linked mutation in the CDKL5 gene. Although clinical presentation varies, the disorder typically manifests as early onset epilepsy within the first few months of life which is commonly drug resistant. Current therapeutic options fall short, offering only symptom-based management that provide minimal improvement in their quality of life. Advancing therapies that directly target the underlying molecular and cellular pathologies of this disease is crucial to developing effective treatments for patients. Several key substrates of CDKL5 are also regulated by CDKL2. Previous studies have identified approved pharmaceuticals capable of increasing CDKL2 levels in the brain. Our lab’s work shows that these drugs not only increase CDKL2 expression in CDKL5 KO mice, but restore the phosphorylation of critical proteins lost with a CDKL5 mutation while also improving behavioural deficits. These findings strongly suggest that such drugs may also ameliorate the seizure phenotype characterized in the mouse models which is one of the disorder’s major comorbidities and the focus of my investigations. This strategy which repurposes a drug is incredibly advantageous as it reduces research and production costs, shortens development timelines, and benefits from the established clinical safety of existing medications. This research is extremely promising however more information is required before patients can have access to these therapeutics. Effect on epileptiform activity, dose response, chronic treatment and evaluation of dual treatments need to all be tested to take a step towards clinical trials.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572737
Name
Fiaani Talia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Proteosome and Lysosome Modulation as a Therapeutic Approach for CDKL5 Deficiency Disorder
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cdkl2; Cdkl5; Cdkl5 Deficiency Disorder; Developmental Disorders; Epilepsy; Epileptic Encephalopathies; Excitatory Synapses; Neurodevelopmental Disease; Proteasome Inhibition; Rare X-Linked Genetic Disorders
Abstract
Cyclin-dependant kinase-like 5 (CDKL5) deficiency disorder is a severe neurodevelopmental disorder caused by an X-linked mutation in the CDKL5 gene. Although clinical presentation varies, the disorder typically manifests as early onset epilepsy within the first few months of life which is commonly drug resistant. Current therapeutic options fall short, offering only symptom-based management that provide minimal improvement in their quality of life. Advancing therapies that directly target the underlying molecular and cellular pathologies of this disease is crucial to developing effective treatments for patients. Several key substrates of CDKL5 are also regulated by CDKL2. Previous studies have identified approved pharmaceuticals capable of increasing CDKL2 levels in the brain. Our lab’s work shows that these drugs not only increase CDKL2 expression in CDKL5 KO mice, but restore the phosphorylation of critical proteins lost with a CDKL5 mutation while also improving behavioural deficits. These findings strongly suggest that such drugs may also ameliorate the seizure phenotype characterized in the mouse models which is one of the disorder’s major comorbidities and the focus of my investigations. This strategy which repurposes a drug is incredibly advantageous as it reduces research and production costs, shortens development timelines, and benefits from the established clinical safety of existing medications. This research is extremely promising however more information is required before patients can have access to these therapeutics. Effect on epileptiform activity, dose response, chronic treatment and evaluation of dual treatments need to all be tested to take a step towards clinical trials.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fiaani, Talia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~